Novartis has big plans for its much-anticipated heart failure remedy Entresto. The Swiss drugmaker figures it can parlay impressive trial data on the drug into its biggest launch in years--perhaps ever.
Actors cry and laugh on command, but people who have pseudobulbar affect can't control their crying jags or laughing fits.
U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories promise to break out in a big way, and we are not talking just about hepatitis C drugs.
The top 10 companies producing diabetes meds raked in about $62 billion in global sales in 2014, up 5.1% from the previous year, according to a report from data analytics firm GlobalData. Companies such as Novo Nordisk, Sanofi and Merck lead the pack, posting solid gains for their products as they compete for a piece of a rapidly growing market.
The cost-effectiveness watchdogs at the National Institute for Health and Care Excellence have put their money behind biosimilars. Remicade biosimilars, to be exact, in new guidance for treating rheumatoid arthritis.
Pharma ad budgets may be set to dip overall in 2016, but the industry's big spenders will still be shelling out $2 billion each--or more--to promote their drugs, according to an annual spending study.
Inspire Pharmaceuticals' AzaSite is approved to treat bacterial conjunctivitis, more commonly known as pink eye. But that's not all the company hawked it for when it was part of Merck & Co., the U.S. Justice Department says.
It's no secret that Big Pharma isn't winning the popularity contest, as pricing pressures, safety issues and regulatory drama continue to take their toll on drugmakers' reputations. But some companies are faring better than other in the eyes of the American public, racking up points for leadership and good behavior, according to a new report from research firm Reputation Institute.
After last week's expert panel meetings, the FDA may put some label limits on PCSK9 cholesterol drugs. But Sanofi, Regeneron and Amgen can take heart.
Pharma growth in China may be slowing and Europe stalling, but there's one area where drugmakers might actually achieve some big growth, according to McKinsey & Co. That's Africa, a mere $4.7 billion market in 2003 and $20.8 billion a decade later.